Floatz logo

su011248

Adult Grade III Lymphomatoid Granulomatosis

National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Adult Grade III Lymphomatoid Granulomatosis cohort.

Asset / SponsorPhaseRating
cc-5013
Mayo Clinic
Phase 2BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 2BB
PREDNISONE TABLETS
University of Chicago
Phase 1/2BB
Inno-206
University of Chicago
Phase 1/2BB
Deferasirox
Wake Forest University Health Sciences
Phase 2B

View all 27 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →